The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory

Nicolai Franzmeier¹, Anna Rubinski¹, Julia Neitzel¹, Michael Ewers¹ & the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

The single nucleotide polymorphism (SNP) rs744373 in the bridging integrator-1 gene (BIN1) is a risk factor for Alzheimer’s disease (AD). In the brain, BIN1 is involved in endocytosis and sustaining cytoskeleton integrity. Post-mortem and in vitro studies suggest that BIN1-associated AD risk is mediated by increased tau pathology but whether rs744373 is associated with increased tau pathology in vivo is unknown. Here we find in 89 older individuals without dementia, that BIN1 rs744373 risk-allele carriers show higher AV1451 tau-PET across brain regions corresponding to Braak stages II–VI. In contrast, the BIN1 rs744373 SNP was not associated with AV45 amyloid-PET uptake. Furthermore, the rs744373 risk-allele was associated with worse memory performance, mediated by increased global tau levels. Together, our findings suggest that the BIN1 rs744373 SNP is associated with increased tau but not beta-amyloid pathology, suggesting that alterations in BIN1 may contribute to memory deficits via increased tau pathology.
Alzheimer’s disease (AD) is the most common cause of late onset dementia and is characterized by the development of pathological amyloid plaques and tau tangles in the brain. While late onset AD is an age-related disease, results from twin and family studies have emphasized that ~50% of phenotypic variance in AD can be explained by genetic variations. Recent genome-wide association studies (GWAS) have identified several loci that are associated with increased risk of AD, among which the single nucleotide polymorphisms (SNPs) in the bridging integrator 1 (BIN1) gene show the second highest odds ratios for sporadic AD, superseded only by apolipoprotein E (APOE) variants. Specifically, the most frequently reported BIN1 AD risk variant is the SNP rs744373 which shows a global allele frequency of 37% and is associated with an increase in AD risk by an odds-ratio of 1.17–1.19. Thus, understanding the mechanisms by which BIN1 and in particular the rs744373 SNP contributes to AD risk will lead to a better understanding of the pathomechanisms of AD and help uncover novel therapeutic targets.

The BIN1 gene encodes the nucleocytoplasmic adaptor protein BIN1 also known as amphiphysin-2, a membrane deforming protein that is most highly expressed in muscle and brain tissue in an isoform-dependent way. In the brain, BIN1 subserves multiple functions such as regulating endocytosis, cytoskeleton integrity, and apoptosis. A key hypothesis for the role of BIN1 in AD is the aggravation of tau pathology, i.e. a key primary brain pathology associated with cognitive impairment in AD. In post-mortem studies in AD, higher brain BIN1 expression was found to be associated with the presence of neurofibrillary tau tangles. Importantly, previous studies have described higher BIN1 mRNA expression in brain tissue of BIN1 risk SNP carriers with and without AD. Further, AD patients carrying a BIN1 risk SNP showed higher post-mortem tau pathology but not Aβ when compared to non-carrier AD patients. Together these findings suggest that BIN1 SNP-associated alterations in BIN1 expression contribute to the development of tau pathology. Although the mechanisms that link BIN1 to tau pathology are only poorly understood, recent findings suggest that alterations in the protein level of a neuron-specific BIN1 isoform that binds exclusively to clathrin, enhance transmission of tau between neurons via enhanced endocytosis of tau. Thus, alterations in BIN1 may promote prion-like spreading of tau within the brain. Alternatively, alterations in BIN1 may be associated with beta-amyloid (Aβ1–42). Post-mortem analyses in AD have shown that BIN1 accumulates in the vicinity of amyloid plaques. In primary neuronal cultures, BIN1 was found to regulate the intraneuronal cleavage of the amyloid precursor protein (APP) by β-secretase. However, the BIN1-mediated increase in the intraneuronal pool of Aβ1–42 only weakly translated into higher extraneuronal levels of Aβ1–42, i.e., a core feature of AD, and several histochemical brain autopsy and cell culture studies suggested that alterations in BIN1 expression were associated with stronger tau pathology rather than Aβ.

Together, these findings from preclinical studies suggest that the risk conferred by BIN1 genetic variants may be exerted via promoting tau pathology rather than Aβ in the brain. Up to now, the translation of these findings to patients with AD using in vivo biomarkers of tau pathology has been difficult. In mild cognitive impairment (MCI) and AD dementia, the BIN1 rs744373 SNP was reported to be associated with higher cerebrospinal fluid (CSF) levels of total and phospho-tau but not with Aβ, whereas others could not detect an association between the BIN1 rs744373 SNP and CSF tau or phospho-tau levels. However, CSF-phospho-tau levels are only moderately associated with neurofibrillary tangles in the brain as assessed post-mortem or by tau-PET imaging. Furthermore, CSF tau levels may reflect differences in tau production rather than the amount of pathological tau deposits in the brain. A previous MRI neuroimaging study showed that a BIN1 SNP was associated with decreased cortical thickness in the entorhinal cortex and temporal pole, i.e., sites of early tau pathology. However, that study did not assess tau pathology itself. Thus, the question remains, whether the BIN1 rs744373 SNP is associated with increased tau pathology in subjects with AD.

The introduction of AV1451 tau-PET imaging allows to assess fibrillary tangles in the living brain. Here we employ AV1451 PET imaging in elderly subjects in order to translate previous preclinical and post-mortem findings on the association BIN1 and primary AD pathology. We assess whether carriers of the BIN1 rs744373 SNP show elevated regional levels of AV1451 tau-PET in those brain regions that are known to show increased susceptibility to tau pathology as defined by the post-mortem established Braak staging. We test the associations of the BIN1 rs744373 SNP in non-demented subjects to understand whether the BIN1 SNP is associated with tau in the early stages of the development of tau pathology. In addition, given previous evidence of a potential involvement of BIN1 rs744373 in Aβ pathology, we assess whether the BIN1 rs744373 SNP is associated with higher regional Aβ deposition as assessed by AV45-PET in the same subjects. We hypothesize that carriage of the BIN1 rs744373 risk-allele selectively enhances tau pathology. Since BIN1 genetic variants were previously associated with faster cognitive decline, we lastly test whether alterations in AV1451 tau-PET levels mediate the association between the BIN1 rs744373 SNP and worse memory performance.

Results
Sample characteristics. For the current study, we analyzed data from 89 participants of the ADNI cohort, including 49 cognitively normal (CN) and 40 mild cognitively impaired (MCI) subjects (see Table 1 for sample characteristics). All subjects underwent AV1451 tau-PET, AV45-amyloid PET, structural MRI and cognitive testing at the same study visit of ADNI phase 3. The genotype of the BIN1 rs744373 SNP was extracted from ADNI GWAS data provided by the ADNI genetics core, where we found 22 CN subjects and 18 MCI subjects to carry at least one copy of the BIN1 rs744373 G-allele which confers higher risk of AD dementia as shown by GWAS. Henceforth, these subjects will be referred to as BIN1 rs744373 risk-allele carriers. BIN1 rs744373 allele distribution (GG/GA/AA = 8/32/49) did not deviate from Hardy–Weinberg equilibrium (p = 0.422, Chi-squared test). There were no differences in baseline demographics (age, gender, education) between CN vs. MCI or between BIN1 rs744373 risk-allele vs. normal-allele carriers. In total, 48 subjects (24 CN & 24 MCI) showed abnormally elevated Aβ levels as determined via AV45 PET (i.e., global standardized uptake value ratio (SUVR) > 1.11).

The BIN1 rs744373 is associated with higher tau-PET uptake. In a first step, we tested the hypothesis that BIN1 rs744373 risk-allele carriers show higher tau pathology (i.e., global or for regions corresponding to Braak stages I–VI, Fig. 1a) than carriers of the normal BIN1 rs744373 allele. For global tau, we quantified the overall tau load as global AV1451 tau-PET uptake using an established Freesurfer-based protocol (i.e., standardized volume uptake ratio normalized to the inferior cerebellar gray). When testing via ANCOVA whether the BIN1 rs744373 SNP had an effect on global AV1451 tau-PET uptake, we found risk-allele carriers to show elevated global tau levels with a Cohens d of 0.562, controlling for age, gender, education, ApoE ε4 status, diagnosis, and gray matter (GM) volume of the global tau ROI.
increases in tau. These analyses are summarized in Fig. 2a and applying a Bonferroni-corrected stage 5 AV1451 tau-PET SUVR remained significant after a Bonferroni-corrected α-threshold of 0.0071 (i.e., α = 0.05 adjusted for 7 tests). Again, these results remained fully consistent when additionally controlling for amyloid levels (i.e., global AV45 amyloid-PET SUVR) as summarized in Table 2 (shown as model 2). Results remained also unchanged when controlling for Aβ status. These findings suggest that the effects of BIN1 rs744373 on AV1451 tau-PET uptake are independent of Aβ or diagnosis.

When testing, whether the BIN1 rs744373 SNP had an effect on amyloid load, we did not detect any differences between risk-allele and normal-allele carriers for global AV45 amyloid-PET SUVR, controlling for age, gender, education, ApoE ε4 status, diagnosis, and GM volume of the respective amyloid ROI (F(81,7) = 0.148, p = 0.701, ANCOVA). To address potential effects of BIN1 rs744373 on regional amyloid levels, we quantified amyloid SUVRs within four distinct early- to late-amyloid stage ROIs (Fig. 1b) that have been previously shown to recapitulate amyloid spread. In line with the results for global AV45 amyloid-PET uptake, we found no significant effect of the BIN1 rs744373 SNP on AV45 amyloid-PET uptake within the different amyloid stage ROIs (all p > 0.05, ANCOVAs, see Fig. 2b & Table 3 for statistics), when controlling for age, gender, education, ApoE ε4 status, diagnosis, and GM volume of the respective, amyloid-stage ROIs. All results remained consistent when additionally including global AV1451 tau-PET SUVRs as a covariate (see Table 3). Again, there was no interaction between diagnosis and BIN1 rs744373 or between global AV45 tau-PET uptake and BIN1 rs744373 on AV45 amyloid-PET uptake.

**BIN1 rs744373 effects on tau are independent of amyloid.** Next, we tested whether BIN1 rs744373 risk-allele carriage was associated with higher tau independent of the level of amyloid. Using linear regression controlling for age, gender diagnosis and ApoE ε4 status, we found that both global AV45 amyloid-PET SUVR (t(81) = 2.506, β = 0.248, p = 0.014) and BIN1 rs744373 (t(81) = 2.882, β = 0.280, p = 0.005) had independent main effects on global AV1451 tau-PET SUVR. No interaction between Aβ status (binary) or global AV45 amyloid-PET SUVR (continuous) and BIN1 rs744373 on AV1451 tau-PET was found. To illustrate the main effect of BIN1 rs744373 effects on AV1451 tau-PET that was independent of AV45 amyloid-PET, we have plotted the association between BIN1 rs744373 and global AV1451 tau-PET uptake at each quartile of global AV45 amyloid-PET (Fig. 3).
test this hypothesis, we obtained whole-brain mRNA expression levels of BIN1 from the Allen Brain Atlas, which is based on post-mortem brain-wide microarray assessments of six healthy brain donors without any history of psychiatric or neurological disorders. Specifically, we used the median of microarray-based log mRNA expression of BIN1 across the six donors that have been recently summarized for each region of the FreeSurfer-based Desikan–Killiany atlas. For the same atlas regions, we determined the group–median AV1451 tau-PET SUVR across all subjects in the current study. We restricted the analysis to the left hemisphere since full mRNA expression data of all six brain donors is only available for this hemisphere. Surface renderings of both group average left hemispheric tau and BIN1 mRNA expression are depicted in the upper panel of Fig. 4. We used spatial regression on 10,000 bootstrapped samples based on which group–median tau levels were iteratively determined to assess the association between group–median AV1451 tau-PET SUVR and BIN1 mRNA expression patterns. Here, we found a significant average positive Pearson–Moment correlation \( r = 0.374 \), see Fig. 5 with a 95% CI of \([0.370,0.379]\) \( p < 0.001 \). These results suggest that regions with higher BIN1 mRNA expression have a higher likelihood of showing elevated tau levels. In order to assess the spatial overlap of regions with high BIN1 expression or high AV1451 tau-PET uptake, we thresholded both the group–median tau PET and the BIN1 mRNA expression maps at a percentile threshold of 75%, (Fig. 4 lower panel). Visual inspection suggests that mesio- and inferior temporal brain regions corresponding to early Braak stages show both high BIN1 mRNA expression as well as high AV1451 tau-PET uptake.

**Tau mediates BIN1 rs744373 effects on memory impairment.** To assess whether the BIN1 rs744373 SNP is detrimental for cognition via increasing tau pathology, we tested whether risk-allele carriage is associated with worse memory and whether these effects are mediated via increased tau pathology. To this end, we applied causal mediation analysis with 10,000 bootstrapping iterations controlling for age, gender, education, diagnosis, global AV45 amyloid-PET SUVR, and ApoE ε4 status. Memory performance was assessed based on ADNI-MEM, which is an established composite score developed by the ADNI core that summarizes the performance on multiple memory tests. Supporting our hypothesis, we found that the BIN1 rs744373 risk-allele was significantly associated with worse ADNI-MEM scores \( \beta = -0.25, p = 0.030 \), where this association was mediated via global AV1451 tau-PET uptake (bootstrapped average causal mediation effect: \( \beta = -0.083 [-0.180,0.000], p = 0.016 \)). The effect was considered a full mediation, since the direct effect of the BIN1 rs744373 risk allele on ADNI-MEM was no longer significant \( \beta = -0.17, p = 0.15 \) in the presence of the mediator (i.e., global AV1451 tau-PET uptake). A path model of this mediation analysis is shown in Fig. 6.

**Discussion**
The major finding of the current study was that the BIN1 rs744373 risk allele was associated elevated AV1451 tau-PET uptake. In contrast, we detected no association between BIN1 rs744373 and regional Aβ assessed by AV45-PET, suggesting that BIN1 is associated with higher tau pathology rather than Aβ. In addition, we found BIN1 rs744373 to be associated with worse memory performance, where this effect was mediated by BIN1 rs744373-associated elevation of global AV1451 tau-PET. Together, our findings support the hypothesis that the BIN1 rs744373 risk-allele is associated with elevated cerebral tau pathology, thereby worsening memory decline. Our findings represent an important contribution to the understanding of the role of BIN1.
in AD, as we demonstrate in living non-demented elderly subjects an association of BIN1 rs744373 and regional elevation of tau pathology, i.e., a key AD pathology associated with cognitive impairment.

For our first finding, the association between BIN1 rs744373 and higher AV1451 tau-PET ROI values but not AV45 amyloid-PET, suggests a selective association between the BIN1 rs744373 SNP and PET-assessed tau pathology. Of note, we did not find an interaction between BIN1 rs744373 and AV45 amyloid-PET on AV1451 tau-PET levels, suggesting that the association between BIN1 and tau does not depend on the presence of Aβ pathology. Supporting this notion, effects of BIN1 rs744373 on AV1451 tau-PET levels remained consistent when controlled for Aβ-status or continuous AV45 amyloid-PET levels. These findings are in general agreement with several previous findings suggesting that BIN1 is linked to tau pathology rather than amyloid pathology. Here, it has been previously reported that brain BIN1 protein levels are correlated with neurofibrillary tangle pathology but not with diffuse or neuritic amyloid plaques in AD brains. In a similar vein, BIN1 risk variants have been previously shown to correlate with post-mortem assessed brain levels of AT8 positive tau pathology but not with Aβ. In contrast, one previous study showed that BIN1 becomes insoluble and accumulates in the vicinity of amyloid plaques in a mouse model of AD and in brain sections from AD patients. Still, it is unclear whether BIN1 alterations are a cause or a consequence of amyloid pathology. Our current results suggest that the BIN1 rs744373 risk allele is associated primarily with PET-assessed tau rather than amyloid levels.

The current results are also in agreement with previous reports of BIN1 rs744373 risk-allele carriage being associated with increased CSF-phospho-tau and CSF-total tau levels but not with CSF-Aβ levels and amyloid PET. We caution however that our current finding of absence of an association between BIN1 rs744373 and AV45 amyloid-PET may partially be due to the

<Table 1 Sample characteristics>

|                      | CN BIN1 Normal (n = 27) | CN BIN1 Risk (n = 22) | MCI-BIN1 normal (n = 22) | MCI-BIN1 risk (n = 18) | p-value |
|----------------------|------------------------|-----------------------|--------------------------|------------------------|---------|
| Age                  | 80.3 (6.09)            | 80.25 (5.55)          | 76.48 (8.13)             | 77.03 (6.35)           | 0.118   |
| Gender (m/f)         | 14/13                  | 11/11                 | 11/11                    | 10/8                   | 0.984   |
| Education            | 17.07 (2.38)           | 16.64 (2.94)          | 15.45 (3.47)             | 15.78 (2.67)           | 0.349   |
| Aβ-status (pos/neg)  | 12/15                  | 12/10                 | 12/10                    | 12/6                   | 0.846   |
| ApoE ε4 pos/neg      | 8/19                   | 5/17                  | 8/14                     | 3/15                   | 0.587   |
| MMSE                 | 29.15 (1.19)           | 28.41 (2.22)          | 27.95 (2.06)             | 28.22 (1.40)           | 0.112   |
| ADNI-MEM             | 0.93 (0.51)c,d         | 0.79 (0.43)d          | 0.43 (0.75)p             | 0.09 (0.43)a,b         | <0.001  |
| AV45 global SUVR     | 1.15 (0.23)            | 1.15 (0.24)           | 1.18 (0.21)              | 1.13 (0.26)            | 0.929   |
| AV1451 global SUVR   | 1.05 (0.12)            | 1.09 (0.07)d          | 1.08 (0.10)d             | 1.18 (0.15)a,b,c       | 0.002   |

CN: Cognitively Normal; MCI: Mild Cognitive Impairment; M: Male; F: Female; MMSE: Mini-Mental State Exam; ADNI-MEM: Alzheimer’s Disease Neuroimaging Initiative-Memory composite

<Table 2 BIN1 rs744373 risk allele as a predictor of AV1451 tau-PET SUVR>

| Dependent variable | AV1451 SUVR: rs744373 risk | AV1451 SUVR: rs744373 normal | Model 1: F | Model 1: P | Model 2: F | Model 2: p | Cohens d |
|--------------------|----------------------------|-------------------------------|------------|------------|------------|------------|----------|
| Global             | 1.13 (0.12)                | 1.06 (0.12)                   | 7.694      | 0.007a     | 7.658      | 0.007a     | 0.562    |
| Braak 1            | 1.23 (0.23)                | 1.17 (0.24)                   | 2.526      | 0.116      | 2.496      | 0.118      | 0.250    |
| Braak 2            | 1.17 (0.23)                | 1.18 (0.20)                   | 4.809      | 0.0311     | 4.749      | 0.0322     | 0.465    |
| Braak 3            | 1.13 (0.15)                | 1.13 (0.13)                   | 4.996      | 0.028b     | 4.992      | 0.028b     | 0.430    |
| Braak 4            | 1.19 (0.16)                | 1.12 (0.12)                   | 6.920      | 0.010c     | 6.883      | 0.010c     | 0.496    |
| Braak 5            | 1.12 (0.12)                | 1.05 (0.19)                   | 9.165      | 0.003a     | 9.087      | 0.003a     | 0.594    |
| Braak 6            | 1.03 (0.08)                | 0.98 (0.11)                   | 5.330      | 0.0245     | 5.263      | 0.0245     | 0.463    |

Model 1 Covariates: age, gender, education, diagnosis, ROI gray matter, ApoE ε4; Model 2 Covariates: Global AV45 amyloid-PET, age, gender, education, diagnosis, ROI gray matter, ApoE ε4

*Significant at p < 0.05 (uncorrected)

<Table 3 BIN1 rs744373 risk allele as a predictor of AV45 amyloid-PET SUVR>

| Dependent variable | AV45 SUVR: rs744373 risk | AV45 SUVR: rs744373 normal | Model 1: F | Model 1: P | Model 2: F | Model 2: p | Cohens d |
|--------------------|--------------------------|-----------------------------|------------|------------|------------|------------|----------|
| Global             | 1.14 (0.24)              | 1.16 (0.22)                 | 0.148      | 0.701      | 0.148      | 0.702      | 0.079    |
| Stage 1            | 1.25 (0.21)              | 1.26 (0.19)                 | 0.111      | 0.739      | 0.111      | 0.740      | 0.052    |
| Stage 2            | 1.18 (0.23)              | 1.20 (0.21)                 | 0.263      | 0.609      | 0.261      | 0.610      | 0.086    |
| Stage 3            | 1.15 (0.17)              | 1.17 (0.16)                 | 0.701      | 0.405      | 0.694      | 0.407      | 0.156    |
| Stage 4            | 1.00 (0.17)              | 1.01 (0.10)                 | 0.118      | 0.732      | 0.118      | 0.732      | 0.068    |

Model 1 Covariates: age, gender, education, diagnosis, ROI gray matter, ApoE ε4; Model 2 Covariates: Global AV451 tau-PET, age, gender, education, diagnosis, ROI gray matter, ApoE ε4

*Significant after Bonferroni correction for 7 tests (p < 0.0071)
fact that in many subjects amyloid may have reached already plateau levels, leading to reduced variability in AV45 amyloid-PET levels. Thus, it is still possible that BIN1 is associated with Aβ pathology especially at the early presymptomatic phase before a plateau is reached.

The molecular mechanisms underlying the association between BIN1 genetic variants and increased AD risk are not known. For the link between BIN1 and tau pathology, in vitro studies showed that BIN1 binds to tau via a proline rich SH3 domain, possibly reducing the integrity of the cytoskeleton. Our findings of a spatial match between the BIN1 mRNA expression pattern in the brain and regions of increased AV1451 tau-PET uptake support the notion that BIN1 SNP-related alterations of BIN1 expression are associated with tau pathology. It is unclear, however, whether the binding of BIN1 to tau entails the development of pathological fibrillary tau. Alternatively, BIN1 may enhance spreading of pathological tau across connected neurons via endocytosis, i.e., a pathway that has recently been suggested to lead to prion-like spreading of tau in the brain. The neuron-specific BIN1 isoform 1 interacts with clathrin, thereby attenuating the post-synaptic endocytotic uptake of tau. Recent histological brain-autopsy studies showed that while BIN1 protein expression is overall increased in AD, the BIN1 isoform 1 is decreased in AD. Together, these results suggest that reduced BIN1 isoform 1 levels may enhance the endocytosis-mediated spreading of tau pathology in AD. However, it is unknown whether the BIN1 genetic variants are associated with reduced BIN1 isoform 1 expression and future studies need to clarify the exact pathomechanisms of BIN1 alterations.

Our second major finding was that the association between BIN1 rs744373 and memory impairment was mediated via elevated global tau levels. This suggests that BIN1 rs744373 contributes to the development of tau pathology in at-risk subjects, resulting in stronger cognitive impairment. These results are in agreement with previous findings of BIN1 rs744373 being associated with faster decline in global cognition and episodic memory. Our results are also consistent with previous studies that...
showing a close association between tau PET and cognitive decline33,49. Our mediation analysis suggests that the BIN1 rs744373 SNP is linked to memory impairment due to the increase in tau pathology in the BIN1 rs744373 risk-allele carriers. We caution that the study design is correlational in nature and thus a causative interpretation should not be drawn. However, our findings provide a putative pathomechanistic link between the BIN1 rs744373 SNP and the increase in dementia risk as reported by GWAS.

We point out several caveats that should be considered when interpreting the results of the current study. Firstly, there are several BIN1 genetic variants associated with an increased risk of AD9,14,15, the rs744373 SNP is linked to memory impairment due to the increase in tau pathology in the BIN1 rs744373 risk-allele carriers. Secondly, we caution that even though the current findings suggest that BIN1 rs744373 is associated with tau pathology, other pathomechanisms of BIN1 may contribute to the increased risk of AD51. The BIN1 protein is highly expressed in the white matter (WM) and oligodendrocytes52 and BIN1 is a key driver of a oligodendrocyte-associated genetic co-expression network that is dysregulated in AD53. These results suggest that BIN1 is associated with altered oligodendrocyte integrity that may contribute to white-matter alterations that are a core part of AD-related pathological changes54,55. Also, BIN1 has been shown to interact with physiological tau in vitro, i.e., a key constituent of microtubules15. It is thus possible, that alterations of BIN1 in the white matter increase the development of pathological tau, which manifests distantly as neurofibrillary tau tangles in the soma. The current results are not in conflict with those alternative pathomechanisms, as the ubiquitously expressed BIN1 protein subserves multiple diverse functions in the brain12,14, and may thus be involved in multiple AD-related pathological pathways.

Thirdly, the AV1451 tau-PET tracer has previously shown off-target binding in the meninges, basal ganglia, and choroid plexus, which may confound the assessment of tau pathology in cortical and subcortical brain regions56. To address this, we excluded ROIs covering the basal ganglia in our analysis to avoid known off-target

The different SNPs on the BIN1 gene may be in disequilibrium and may add independently from each other to the risk of AD14. Here, we focused on rs744373 because this SNP is most frequently reported to be associated with AD across different GWAS studies3,7 (see also AlzGene database at http://www.alzgene.org/)50. Although rs744373 is the primary BIN1 SNP associated with increased AD risk, a previous study suggested that the Indel rs59335482 is associated with increased BIN1 mRNA in post-mortem analyzed brains from AD patients, suggesting that rs59335482 is the functionally effective BIN1 genetic variant associated with AD risk. However, the Indel rs59335482, which was not available in the current GWAS, is in almost complete linkage equilibrium with rs74437315, suggesting both SNPs share redundant predictive value. Furthermore, control analysis using an alternative SNP rs7561528 that was available from the GWAS analysis, i.e., another frequently reported BIN1 SNP as a risk factor of AD14, confirmed the association between the BIN1 SNP and increased regional AV1451 tau-PET, suggesting that the current findings were not specific to rs744373 as a tau-related genetic variant of BIN1.

Fig. 5 Association between tau-PET and BIN1 mRNA expression. Scatterplot showing the positive association between ROI-based BIN1 mRNA expression obtained from the Allen Brain Atlas and group-median AV1451 tau-PET uptake (Number of ROIs = 34; Association illustrated as least-squares regression line ±95% confidence interval). P-values and 95% confidence intervals of r-values are derived from bootstrapped spatial regression with 1000 iterations.
binding sites to confound our analyses. However, in the current study the AV1451 signal within the hippocampus may be affected by off-target binding in the choroid plexus, hence these results await replication using second generation tau tracers with a better off-target binding profile. Importantly, however, the BIN1 rs744373 association with higher tau was not limited to the hippocampal AV1451 tau-PET, but was widespread within the brain, rendering it highly unlikely that spill-off from regions of unspecific AV1451 tracer binding accounted for the current results.

In conclusion, our results show an association between BIN1 rs744373 risk-allele carriage and in vivo assessed tau pathology in elderly subjects with and without amyloid pathology. The current findings suggest that tau pathology provides a key link that underlies the association between BIN1 genetic variants and cognitive impairment. Future studies may further test whether BIN1 risk variants are associated with higher rates of increases in pathological tau and faster cognitive decline and conversion to dementia. It is currently unclear whether BIN1 genetic variants are associated with tauopathies other than AD. A recent study reported an association between BIN1 rs744373 and frontotemporal dementia37, however, the association between BIN1 and tau pathology in conditions other than AD remains to be tested in the future. From a clinical point of view, our findings encourage future research in targeting BIN1 protein modification as a potential therapeutic approach to reduce levels of tau pathology.

Preclinical studies showed that knock-down of BIN1 reduced tau-related toxicity in a drosophila model of neurodegeneration15. Understanding the exact mechanisms of the association between BIN1 and tau pathology are of pivotal clinical importance, since tau is the best predictor of clinical severity in contrast to Aβ deposition.58 Neuroimaging of tau PET may be a marker to monitor treatment effects of disease modifying therapies targeting BIN1.

Methods

Study design. We included 89 participants from ADNI phase 3 (ClinicalTrials.gov ID: NCT02854033) in whom 18F-AV1451 tau-PET was obtained. 18F-AV1451 PET was added only in phase 3 of ADNI, and is thus only available in a smaller subset of the large ADNI cohort. The current set of 89 subjects resulted from inclusion criteria of the availability of T1-mtMRI, 18F-AV45 amyloid-PET, cognitive and GWAS data in addition to 18F-AV1451 tau-PET. All imaging modalities had to be obtained at the same study visit. Selection bias was tested against the entire ADNI cohort of 1784 subjects. Here, we found no differences in gender or education between our selected sample and the entire ADNI sample, however, the mean age of the selected sample (~78.7 years) was significantly (p < 0.05) higher than the mean age of the entire ADNI cohort (~73.7 years). Subjects were clinically classified by ADNI centers as cognitively normal (C, MMSE > 24, CDR = 0, non-depressed) or mild cognitively impaired (MCI; MMSE > 24, CDR = 0.5, objective memory-loss on the education adjusted Wechsler Memory Scale II, preserved activities of daily living). Subjects with AD dementia were excluded from the analysis due to the small number of cases that met our inclusion criteria (n = 3). The BIN1 rs744373 genotype was extracted from GWAS data provided by the ADNI genetics core, where whole-genome sequencing was conducted using the Illumina Omni 2.5 M Bead Chip. For a detailed description of the whole-genome sequencing methods, please refer to a previous publication by the ADNI genetics core, where whole-genome sequencing was conducted using the Illumina Omni 2.5 M Bead Chip. For a detailed description of the whole-genome sequencing methods, please refer to a previous publication by the ADNI genetics core. Subjects were assigned to the BIN1 rs744373 risk-group (n = 40) when carrying at least one G-allele. Ethical approval was obtained by the ADNI investigators at each study site, all participants provided written informed consent and all work complied with ethical regulations for work with human participants.

Image acquisition. All imaging data was downloaded from the ADNI loni image archive (https://linda.loni.ucsd.edu). Structural MRI in ADNI3 was recorded using a 3D T1-weighted MPGRAGE sequence with 1 mm isotropic voxel-space and a TR = 2300 ms. Detailed sequence parameters can be found online at (http://linda.loni.ucsd.edu/wp-content/uploads/2017/07/ADNI3-MRI-protocols.pdf).

18F-AV1451 tau-PET was acquired 75–105 min post-injection of 18F-AV1451, in 6 × 5 minute time frames. 18F-AV-45 Flortetapam amyloid PET scans were obtained during 4 × 5 min time frames measured 50–70 min post-injection of 18F-AV45 (http://adni.loni.ucsd.edu/wp-content/uploads/2010/05/ADNI2_PET_Tech_Manual_012011.pdf).

For both AV1451 tau- and AV45 amyloid-PET we downloaded partially preprocessed data where dynamically acquired image frames are first registered to an AC-PC orientation and standard voxel image grid and subsequently averaged to obtain a single image for each PET modality. Having PET images in a standard image matrix facilitates the combination of PET images from different scanners. For further details please see refer to the ADNI website (http://adni.loni.usc.edu/methods/pet-analysis/method/pet-analysis/).

Image preprocessing. All MRI and PET images were inspected for artifacts prior to preprocessing. We applied two preprocessing pipelines to PET data, following pre-established protocols to evaluate regional and global AV1451 tau- and AV45 amyloid-PET uptake. First, we used a SPM12-based pipeline to obtain stage-specific AV45 amyloid-PET SUVR scores. Second, we applied a Freesurfer-based pipeline to obtain global AV45 amyloid61 as well as global and regional AV1451 tau-PET SUVRs (i.e., Braak stage ROIs)33.

For the pre-established SPM12-based pipeline62–67, native-space structural MNI images into were first segmented into gray matter (GM), white matter (WM) and CSF maps using SPMs new segment approach. Using SPMs high-dimensional DARTEL warping algorithm, we estimated subject-specific flow-fields to non-linearly transform all GM, WM, and CSF maps to a sample-speciﬁc template that was determined in an iterative procedure. Using affine transformation, this sample-speciﬁc template was then warped to a standardized Neurological Institute (MNI) standard space. Next, subject-specific AV45 amyloid-PET images were co-registered to the corresponding high-resolution T1 image and subsequently DARTEL warped to MNI standard space. We did not spatially smooth the images to avoid spill over between adjacent regions during ROI-based analyses.

For the Freesurfer-based pipeline (Version 5.3), we applied volumetric segmentation to the high-resolution native-space structural MRI images, where subcortical and cortical areas are segmented automatically using the probabilistic Desikan–Killiany Atlas68. The segmented anatomical ROIs from the high-resolution structural MRI images were then applied to the co-registered AV45 amyloid- and AV1451 tau-PET images to extract ROI-based values. To obtain SUVR scores, all ROI values were normalized to the mean uptake of the whole cerebellum for AV45 data, and to the mean uptake of the inferior cerebellar gray for AV1451 data, following previous recommendations32,69.

Amyloid staging. For AV45 amyloid PET, we assessed global amyloid-PET levels that are commonly used for subject stratiﬁcation into Aβ-positive/negative plus a more ﬁne-grained anatomical amyloid staging system that was introduced recently34. For global amyloid load we computed global AV45 amyloid-PET SUVRs using an established Freesurfer pipeline. In brief, we averaged Freesurfer-deﬁned SUVR (normalized to the whole cerebellum) scores across lateral and medial frontal, anterior, and posterior cingulate, lateral parietal and lateral temporal regions61. Based on these scores, Aβ-positivity was deﬁned as a global AV45 amyloid-PET SUVR > 1.1169. Summary statistics on amyloid status can be found in table 1.

We further assessed local amyloid levels using a 4-stage model, that suggests amyloid deposition to initiate in the temporobasal and mediofrontal areas with subsequent affectation of the associative neocortex, primary sensorimotor areas and lastly the basal ganglia44. To this end, we used the MNI normalized AV45 amyloid-PET images from our SPM12 pipeline where we determined the mean scores within the four amyloid stage ROIs (shown in Fig. 1b) that were built using the MNI-space based Harvard–Oxford brain atlas following a previously described protocol44. Again, these mean values were intensity normalized to Freesurfer derived whole-cerebellar AV45 uptake to obtain SUVR scores.

Tau staging. For tau, we also obtained global as well as stage-speciﬁc AV1451 tau-PET SUVR scores. For global tau, we averaged the size-weighted Freesurfer-ROI SUVRs across all Desikan–Killiany atlas regions, excluding the cerebellum, thalamus and basal ganglia (i.e., typical regions of AV1451 off-target binding) following a previously described approach32. For stage-speciﬁc AV1451 tau-PET uptake, we applied a recently described Braak-ROI staging system that allows application of the post-mortem established tau staging system to tau PET imaging33. Here, we obtained size-weighted Freesurfer-ROI SUVRs for each Braak stage ROI, from Braak stage I (i.e., entorhinal cortex) to Braak stage VI (i.e., primary sensorimotor & primary visual cortex). A list of ROIs that are included within each Braak stage ROI can be found online (https://adni.bitbucket.io/reference/docs/UCBERKELEYAV1451/UCBERKELEYAV1451_Methods_FINAL.pdf). A surface rendering of the Braak – stage system can be found online (https://adni.bitbucket.io/reference/docs/UCBERKELEYAV1451/UCBERKELEYAV1451_Methods_FINAL.pdf).

mRNA expression levels of BIN1. Regional gene expression was obtained from publicly available microarray measurements of regional mRNA expression based on post-mortem data from the Allen Brain Atlas (http://human.brain-map.org/); RRID: SCR007416). The Allen Brain atlas includes more than 60,000 microarray probes collected from 370 autopsy-based brain tissue samples from a total of 6 subjects aged 24–57 with no known history of neurological or psychiatric conditions35,36. Microarray-based log2 expression values of
20,737 genes within each of the 3700 samples were mapped back into MNI standard space by the Allen Brain Institute using stereotactic coordinates of the respective tau ROI. To assess any effects of the BIN1 rs744373 SNP on amyloid, we tested the same models this time using global or regional (i.e., amyloid-stage ROIs) AV45 amyloid-PET SUVR independent of amyloid. To this end, we conducted linear regression analyses with global or regional (i.e., Braak stage ROIs) AV45 amyloid-PET SUVRs as the dependent variable. Lastly, we tested whether higher local BIN1 mRNA expression levels were associated with an increased likelihood of developing abnormal tau. To this end, we determined BIN1 mRNA expression using the Allen brain atlas data in Desikan–Killiany atlas space and determined the group–median regional tau PET SUVRs for corresponding anatomical regions. We then surface-mapped both group–median tau PET SUVRs and BIN1 mRNA expression and tested the Pearson–Mann–Whitney correlation between regional BIN1 mRNA expression and tau load, using a two-tailed alpha threshold of 0.05. We repeated this analysis based on 10,000 randomly drawn bootstrapped samples to determine the 95% CI of the correlation coefficient between BIN1 mRNA expression and AV45 tau-PET uptake.

Lastly, we assessed whether BIN1 rs744373 risk-allele carriage was associated with hippocampal atrophy using hippocampal atrophy. To test this, we conducted mediation analysis, testing whether the association between BIN1 rs744373 and global brain atrophy was mediated by BIN1 mRNA expression and AV45 tau-PET uptake. Significance of the mediation effect was determined using 10,000 bootstrapped iterations, where each path of the model was controlled for age, gender, education, and diagnosis and ApoE ε carrier status.

All statistical analyses were conducted with R statistical software. P-values were considered significant when meeting a two-tailed alpha threshold of 0.05. When a single hypothesis was tested multiple times, we also report Bonferroni-corrected p-values in case of significant uncorrected p-values.

### Reporting summary
Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.

### Data availability
The data that support the findings of this study were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and are available from the ADNI database (adni.loni.usc.edu) upon registration and compliance with the data use agreement. A list including the anonymized participant identifiers of the currently used sample and the source file can be downloaded from the ADNI database (http://adni.loni.usc.edu). The R-script used for the current study can be obtained from the first author upon request.

Received: 12 November 2018 Accepted: 14 March 2019
Published online: 16 April 2019

### References
1. Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. *EMBO Mol. Med.*, 8, 595–608 (2016).
2. Ridge, P. G. et al. Assessment of the genetic variance of late-onset Alzheimer’s disease. *Neurol. Aging*, 41, 200 e213–200 e220 (2016).
3. Seshadri, S. et al. Genomic analysis of genetic loci associated with Alzheimer disease. *JAMA*, 303, 1832–1840 (2010).
4. Zhu, R., Liu, X. & He, Z. The bridging integrator 1 gene polymorphism rs744373 and the risk of Alzheimer’s disease in caucasian and asian populations: an updated meta-analysis. *Mol. Neurobiol.*, 54, 1419–1428 (2017).
5. Hollingworth, P. et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. *Nat. Genet.*, 43, 429–435 (2011).
6. Wijsman, E. M. et al. Genome-wide association of familial late-onset Alzheimer’s disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. *PLoS Genet.*, 7, e1001308 (2011).
7. Almeida, J. F. F., Dos Santos, L. R., Trancozo, M. & de Paula, F. Updated meta-analysis of BIN1, CR1, MS4A6A, CLU, and ABCA7 variants in Alzheimer’s disease. *J. Mol. Neurosci.*, 64, 471–477 (2018).
8. Antunez, C. et al. The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer’s disease. *Genome Med.*, 3, 33 (2011).
9. Hu, X. et al. Meta-analysis for genome-wide association study identifies multiple variants in the BIN1 locus associated with late-onset Alzheimer’s disease. *PLoS ONE*, 6, e16616 (2011).
10. AlzGene. Meta-Analysis of all published AD association studies (case-control samples) - rs744373. Alzgene.org retrieved on 23 August 2018.
11. Sakamuro, D., Elliott, K. J., Wechsler-Reya, R. & Prendergast, G. C. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. *Nat. Genet.*, 14, 69–77 (1996).
12. Butler, M. H. et al. Amyphophisin II (SH3P9; BIN1), a member of the amyphophisin/Rvs family, is concentrated in the cortical cytomatrix of axon initial segments and nodes of Ranvier in brain and around T tubules in skeletal muscle. *J. Cell. Biol.*, 137, 1355–1367 (1997).
13. Prokic, I., Cowling, B. S. & Laporte, J. Amyphophisin 2 (BIN1) in physiology and diseases. *J. Mol. Med. (Berl)*, 92, 453–463 (2014).
14. Tan, M. S., Yu, J. T. & Tan, L. Bridging integrator 1 (BIN1): form, function, and Alzheimer’s disease. *Trends Mol. Med.*, 19, 594–603 (2013).
15. Chupas, J. et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. *Mol. Psychiatry*, 18, 1225–1234 (2013).
16. Holler, C. J. et al. Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer’s disease brain and correlates with neurofilibrillary tangle pathology. *J. Alzheimers Dis.*, 42, 1221–1227 (2014).
17. Bungenberg, J. et al. Gene expression variance in hippocampal tissue of temporal lobe epilepsy patients corresponds to differential memory performance. *Neurobiol. Dis.*, 86, 121–130 (2016).
18. Wu, J. W. et al. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. *J. Biol. Chem.*, 288, 18686–18690 (2013).
19. Calafate, S., Flavin, W., Verstreken, P. & Moechars, D. Loss of Bin1 promotes the propagation of Tau pathology. *Cell Rep.*, 17, 931–940 (2016).
20. Yu, L. et al. Association of Brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. *JAMA Neurol.*, 72, 42–54 (2015).
21. De Rossi, P. et al. Aberrant accrual of BIN1 near Alzheimer’s disease amyloid deposits in transgenic mice. *Brain Pathology*, 0, 1–17 https://doi.org/10.1111/bpa.12687 (2018).
22. Uebelmann, F. et al. BIN1 and CD2AP polarise the endocytic generation of beta-amyloid. *EMBO Rep.*, 18, 102–112 (2017).
23. Wang, H. F. et al. Bridging Integrator 1 (BIN1) genesotypes mediate Alzheimer’s disease risk by altering neuronal degeneration. *J. Alzheimers Dis.*, 52, 179–190 (2016).
24. Kauwe, J. S. et al. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer’s disease. *PLoS ONE*, 6, e16164 (2011).
25. Buerger, K. et al. CFSP phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. *Brain*, 129, 3035–3041 (2006).
26. La Joie, R. et al. Associations between (18)F-AV1451 tau PET and CSF measures of tau pathology in a clinical sample. *Neurology*, 90, e282–e290 (2018).
27. Mattsson, N. et al. 18F-AV1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease. *EMBO Mol. Med.*, 9, 1212–1223 (2017).
28. Sato, C. et al. Tau kinetics in neurons and the human central nervous system. *Neuron*, 98, 861–864 (2017).
29. Riff, A. et al. Genetic variation and neuroimaging measures in Alzheimer disease. *Arch. Neurol.*, 67, 677–685 (2010).
30. Marquie, M. et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. *Ann. Neurol.* 78, 787–800 (2015).
31. Braak, H. & Braak, E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* 82, 239–259 (1991).
32. Maass, A. et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer’s disease. *Neuroimage* 157, 448–463 (2017).
33. Schöls, L. et al. PET imaging of Tau deposition in the aging human brain. *Neuron* 89, 971–982 (2016).
34. Grothe, M. J. et al. In vivo staging of regional amyloid deposition. *Neurology* 89, 2031–2038 (2017).
35. Hawrylycz, M. et al. Canonical genetic signatures of the adult human brain. *Nat. Neurosci.* 18, 1832–1844 (2015).
36. Marquie, M. J. et al. An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature* 489, 391–399 (2012).
37. French, L. & Paus, T. A FreeSurfer view of the cortical transcriptome generated from the Allen Human Brain Atlas. *Front. Neurosci.* 9, 323 (2015).
38. Crane, P. K. et al. Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). *Brain Imaging Behav.* 6, 502–516 (2012).
39. De Rossi, P. et al. BIN1 localization is distinct from Tau tangles in Alzheimer’s disease. *Matters (Zur)* 1–7 https://doi.org/10.19185/ matters.201611000018 (2017).
40. Villanueva, V. et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. *Lancet Neurol.* 12, 357–367 (2013).
41. Sottejeau, Y. et al. Tau phosphorylation regulates the interaction between BIN1’s SH3 domain and Tau’s proline-rich domain. *Acta Neuropathol. Commun.* 3, 58 (2015).
42. Malik, I. et al. Regulation of the interaction between the neuronal BIN1 isoform 1 and Tau proteins—role of the SH3 domain. *Feb. J.* 284, 3218–3229 (2017).
43. Lasorsa, D. et al. Structural basis of Tau interaction with BIN1 and regulation by Tau phosphorylation. *Front. Mol. Neurosci.* 11, 421 (2018).
44. Franzmeier, N. et al. Functional connectivity associated with tau levels in ageing, Alzheimer’s, and small vessel disease. *Brain* 0, 1–15 https://doi.org/10.1093/brain/awz026 (2019).
45. de Calignon, A. et al. Propagation of tau pathology in a model of early Alzheimer’s disease. *Neuron* 73, 685–697 (2012).
46. Takeda, S. et al. Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer’s disease mouse model and human patients. *Ann. Neurol.* 80, 355–367 (2016).
47. Vivot, A. et al. Association of Alzheimer’s related genotypes with cognitive decline in multiple domains: results from the Three-City Dijon study. *Mol. Psychiatry* 20, 1173–1178 (2015).
48. Baral, S. et al. Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memory. *Neurology* 78, 1464–1471 (2012).
49. Maass, A. et al. Entorhinal Tau pathology, episodic memory decline, and neurodegeneration in aging. *J. Neurosci.* 38, 530–543 (2018).
50. Bertram, L., McQueen, M. B., Mullin, K., Blacker, D. & Tanzi, R. E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. *Nat. Genet.* 39, 17–23 (2007).
51. Karch, C. M. & Goate, A. M. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. *Brain Imaging Behav.* 77, 43–51 (2015).
52. De Rossi, P. et al. Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts. *Mol. Neurodegener.* 11, 59 (2016).
53. McKenzie, A. T. et al. Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer’s disease. *Mol. Neurodegener.* 12, 82 (2017).
54. Mito, R. et al. Fibro-specific white matter reductions in Alzheimer’s disease and mild cognitive impairment. *Brain* 141, 888–902 (2018).
55. Araque Caballero, M. A. et al. White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease. *Brain* 141, 3065–3080 (2018).
56. Marquie, M. et al. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case. *Acta Neuropathol. Commun.* 5, 75 (2017).
57. Ferrari, R. et al. A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. *Neurobiol. Aging* 36, 2904 e2913–2904 e2926 (2015).
58. Aschenbrenner, A. J., Gordon, B. A., Benzing, T., L. S., Morris, J. C. & Hassenstab, J. J. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. *Neurology* 91, e859–e866 (2018).
59. Petersen, R. C. et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology* 74, 201–209 (2010).
60. Saykin, A. J. et al. Genetic studies of quantitative MCI and AD phenotypes in ADN: progress, opportunities, and plans. *Alzheimers Dement.* 11, 792–814 (2015).
61. Landau, S. M. et al. Amyloid-beta imaging with Pittsburgh compound B and flurbipar: comparing radiotracers and quantificationmethods. *J. Nucl. Med.* 54, 70–77 (2013).
62. Rittman, T. et al. Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. *Neurobiol. Aging* 48, 153–160 (2016).
63. Romme, I. A., de Reus, M. A., Ophof, R. A., Kahn, R. S. & van den Heuvel, M. P. Connectome disconnectivity and cortical gene expression in patients with schizophrenia. *Biol. Psychiatry* 81, 495–502 (2017).
64. Grothe, M. J. et al. Molecular properties underlying regional vulnerability to Alzheimer’s disease pathology. *Brain* 141, 2755–2777 (2018).

**Acknowledgements**

Data used in preparation of this manuscript were obtained from the ADNI database (adni.loni.usc.edu). As such, the investigators within the ADNI study contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this paper. The study was funded by grants from the Alzheimer’s Association, the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Arcalion Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).

**Author contributions**

N.F.: study concept and design, data processing, statistical analysis, interpretation of the results, and writing the manuscript. A.R.: data processing and critical revision of the manuscript. J.N.: data processing and critical revision of the manuscript. M.E.: study concept and design, interpretation of the results, and writing the manuscript. ADNI provided all data used for this study.
The Alzheimer's Disease Neuroimaging Initiative (ADNI)

Michael W. Weiner2, Paul Aisen3, Ronald Petersen4, Clifford R. Jack4, William Jagust5, John Q. Trojanowski6, Arthur W. Toga7, Laurel Beckett8, Robert C. Green9, Andrew J. Saykin10, John Morris11, Leslie M. Shaw6, Zaven Khachaturian8,12, Greg Sorensen13, Lew Kuller14, Marcus Raichle11, Steven Paul15, Peter Davies16, Howard Filtl17, Franz Hefli18, David Holtzman11, Marek M. Mesulam19, William Potter20, Peter Snyder21, Adam Schwartz22, Tom Montine23, Ronald G. Thomas23, Michael Donohue23, Sarah Walter23, Devon Gessert23, Tamie Sather23, Gus Jiminez23, Daniille Harvey8, Matthew Bernstein4, Paul Thompson24, Norbert Schuff2,8, Bret Borowski4, Jeff Gunter4, Matt Senjem4, Prashanthi Venuri4, David Jones4, Kajal Kaur4, Chad Ward4, Robert A. Koepp25, Norm Foster26, Eric M. Reiman27, Kewei Chen27, Chet Mathis14, Susan Landau5, Nigel J. Cairns11, Erin Householder11, Lisa Taylor-Reinwald11, Virginia Lee6, Magdalena Korecka6, Michal Figurski6, Karen Crawford7, Scott Neu7, Tatiana M. Foroud10, Steven G. Potkin28, Li Shen10, Kelley Faber10, Sungun Kim10, Kwangsik Nho10, Leon Thal3, Neil Buckholtz29, Marylyn Albert30, Richard Frank31, John Hsiao29, Jeffrey Kaye32, Joseph Quinn32, Betty Lind32, Raina Carter32, Sara Dolen32, Lon S. Schneider7, Sonia Pawluczyn7, Mauricio Beccera7, Liberty Teodor6, Bryan M. Span7, James Brewer3, Helen Vanderswag3, Adam Fleisher3,27, Judith L. Heidebrink25, Joanne L. Lord25, Sara S. Mason4, Colleen S. Albers4, David Knopman4, Kris Johnson4, Rachelle S. Doody33, Javier Villanueva-Meyer33, Munir Chowdhury33, Susan Rountree33, Mimi Dang33, Yaakov Stern33, Lawrence S. Honig33, Karen L. Beil33, Beau Ances11, Maria Carroll11, Sue Leon11, Mark A. Mintun11, Stacy Schneider11, Angela Oliver11, Daniel Marson34, Randall Griffith34, David Clark34, David Geldmacher34, John Brockington34, Erik Roberson34, Hillel Grossman35, Effie Mitsis35, Leyla de Toledo-Morrell36, Raj C. Shah36, Ranjan Duara37, Daniel Varon37, Maria T. Greig37, Peggy Roberts37, Chiadi Onyike30, Daniel D'Agostino30, Stephanie Kielb30, James E. Galvin38, Brittany Cerce38, Christina A. Michel38, Henry Rusinek38, Mony J. de Leon38, Lida Glodzik38, Susan De Santi38, P Murali Doraiswamy39, Jeffrey R. Petrella39, Terence Z. Wong39, Steven E. Arnold6, Jason H. Karlawish6, David Wolk5, Charles D. Smith40, Greg Jicha40, Peter Hardy40, Partha Sinha40, Elizabeth Oates40, Gary Conrad40, Oscar L. Lopez14, MaryAnn Oakley14, Donna M. Simpson30, Anton P. Porsteinsson41, Bonnie S. Goldstein41, Kim Martin41, Kelly M. Makino41, M Saleem Ismail41, Connie Brand41, Ruth A. Mulnard28, Gaby Thai28, Catherine McAdams-Ortiz28, Kyle Womack42, Dana Mathews42, Mary Quiceno42, Ramon Diaz-Arrastia42, Richard King42, Myron Weiner42, Kristen Martin-Cook42, Michael DeVos42, Allan I Levey43, James J. Lah43, Janet S. Cella43, Jeffrey M. Burns44, Heather S. Anderson44, Russell H. Swerdlow44, Liana Apostolova24, Kathleen Tingus24, Ellen Woo24, Daniel H.S. Silverman24, Po H. Lu24, George Bartzokis24, Neill R. Graff-Radford45, Francine Parfitt45, Tracy Kendall45, Heather Johnson45, Martin R. Farlow10, Ann Marie Hake10, Brandy R. Matthews10,
Scott Herring, Cynthia Hunt, Christopher H. van Dyck, Richard E. Carson, Martha G. MacAvoy, Howard Chertkow, Howard Bergman, Chris Hosein, Ging-Yuek Robin Hsiung, Howard Feldman, Benita Mudge, Michele Assaly, Charles Bernick, Donna Munic, Andrew Kertesz, John Rogers, Dick Trost, Diana Kerwin, Kristine Lipowski, Chuang-Kuo Wu, Nancy Johnson, Carl Sadowsky, Walter Martinez, Teresa Villena, Raymond Scott Turner, Kathleen Johnson, Brigid Reynolds, Reisa A. Sperling, Keith A. Johnson, Gad Marshall, Meghan Frey, Barton Lane, Allyson Rosen, Jared Tinklenberg, Marwan N. Sabbagh, Christine M. Belden, Sandra A. Jacobson, Sherye A. Sirrel, Neil Kowall, Ronald Killiany, Andrew E. Budson, Alexander Norbash, Patricia Lynn Johnson, Joanne Allard, Alan Lerner, Paula Ogrocki, Leon Hudson, Evan Fletcher, Owen Carmichael, John Olichney, Charles DeCarli, Smita Kittur, Michael Borrie, T-Y. Lee, Rob Bartha, Sterling Johnson, Sanjay Asthana, Cynthia M. Carlsson, Adrian Preda, Dana Nguyen, Pierre Tariot, Stephanie Reeder, Vernice Bates, Horacio Capote, Michelle Rainka, Douglas W. Scharre, Maria Katak, Anahita Adeli, Earl A. Zimmerman, Dzintra Celmins, Alice D. Brown, Godfrey D. Pearlson, Karen Blank, Karen Anderson, Robert B. Santulli, Tamar J. Kitzmiller, Eben S. Schwartz, Kaycee M. Sink, Jeff D. Williamson, Pradeep Garg, Franklin Watkins, Brian R. Ott, Henry Querfurth, Geoffrey Tremont, Stephen Salloway, Paul Malloy, Stephen Correia, Howard J. Rosen, Bruce L. Miller, Jacobo Mintzer, Kenneth Spicer, David Bachman, Stephen Pasternak, Irina Rachinsky, Dick Drost, Nunzio Pomara, Raymundo Hernandez, Antero Sarrael, Susan K. Schultz, Laura L. Boles Ponto, Hyungsuk Shim, Karen Elizabeth Smith, Norman Relkin, Gloria Chiang, Lisa Raudin, Amanda Smith, Kristin Fargher, Balebail Ashok Raja, Thomas Neylan, Jordan Grafman, Melissa Davis, Rosemary Morrison, Jacqueline Hayes, Shannon Finley, Karl Friedl, Debra Fleischman, Konstantinos Arfanakis, Olga James, Dino Massoglia, J. Jay Fruehling, Sandra Harding, Elaine R. Peskind, Eric C. Petrie, Gary Gli, Jerome A. Yesavage, Joy L. Taylor, Asangar J. Furst.

2UC San Francisco, San Francisco, CA 94143, USA. 3UC San Diego, San Diego, CA 92093, USA. 4Mayo Clinic, Rochester, NY 14603, USA. 5UC Berkeley, Berkeley, CA 94720, USA. 6Upenn, Philadelphia, PA 19104, USA. 7USC, Los Angeles, CA 90089, USA. 8UC Davis, Davis, CA 95616, USA. 9Brigham and Women's Hospital, Boston, MA 02115, USA. 10Indiana University, Bloomington, IN 47405, USA. 11Washington University in St Louis, St Louis, MO 63130, USA. 12Prevent Alzheimer's Disease 2020, Rockville, MD 20850, USA. 13Siemens, Munich 80333, Germany. 14University of Pittsburgh, Pittsburgh, PA 15260, USA. 15Weill Cornell Medical College, Cornell University, New York, NY 10065, USA. 16Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, USA. 17AD Drug Discovery Foundation, New York City, NY 10019, USA. 18Acumen Pharmaceuticals, Livernore, CA 94551, USA. 19Northwestern University, Evanston and Chicago, IL 60208, USA. 20National Institute of Mental Health, Rockville, MA 20852, USA. 21Brown University, Providence, RI 02912, USA. 22Eli Lilly, Indianapolis, IN 46225, USA. 23Washington University, St Louis, MO 63110, USA. 24UC, Salt Lake City, UT 84112, USA. 25Banner Alzheimer's Institute, Phoenix, AZ 85006, USA. 26UC Irvine, Irvine, CA 92697, USA. 27National Institute on Aging, Bethesda, MD 20892, USA. 28John Hopkins University, Baltimore, MD 21218, USA. 29Frank Rich Consulting, Washington, DC 20001, USA. 30Oregon Health and Science University, Portland, OR 97239, USA. 31Baylor College of Medicine, Houston, TX 77030, USA. 32University of Alabama, Birmingham, AL 35233, USA. 33Mount Sinai School of Medicine, New York, NY 10029, USA. 34Rush University Medical Center, Chicago, IL 60612, USA. 35Wien Center, Miami, FL 33140, USA. 36New York University, New York, NY 10003, USA. 37Duke University Medical Center, Durham, NC 27710, USA. 38University of Kentucky, Lexington, KY 40506, USA. 39University of Rochester Medical Center, Rochester, NY 14642, USA. 40University of Texas Southwestern Medical School, Dallas, TX 75390, USA. 41Emory University, Atlanta, GA 30322, USA. 42Medical Center, University of Kansas, Kansas City, KS 66103, USA. 43Mayo Clinic, Jacksonville, FL 32224, USA. 44Yale University School of Medicine, New Haven, CT 06510, USA. 45McGill University/Montreal-Jewish General Hospital, Montreal, QC H3T 1E2, Canada. 46University of British Columbia Clinic for AD & Related Disorders, Vancouver, BC V6T 1Z3, Canada. 47Duke University Medical Center, Durham, NC 27710, USA. 48University of California, San Francisco, CA 94143, USA. 49St Joseph's Health Care, London, ON N6A 4V2, Canada. 50Premiere Research Institute, Palm Beach Neurology, Miami, FL 33407, USA. 51Georgetown University Medical Center, Washington, DC 20007, USA. 52Bannerg Sun Health Research Institute, Sun City, AZ 85351, USA. 53Boston University, Boston, MA 02215, USA. 54Howard University, Washington, DC 20059, USA. 55Case Western Reserve University, Cleveland, OH 44102, USA. 56Neurological Care of CNY, Liverpool, NY 13088, USA. 57Parkwood Hospital, London, ON N6E 0A7, Canada. 58University of Wisconsin, Madison, WI 53706, USA. 59Dent Neurologic Institute, Amherst, NY 14226, USA. 60Ohio State University, Columbus, OH 43210, USA. 61Alberta Medical College, Calgary, AB T2N 2N1, Canada. 62University of Iowa College of Medicine, Iowa City, IA 52242, USA. 63University of South Florida: USF Health Byrd Alzheimer's Institute, Tampa, FL 33613, USA. 64Department of Defense, Arlington, VA 22350, USA. 65Stanford University, Stanford, CA 94305, USA.